325 related articles for article (PubMed ID: 26597600)
1. EMPA-REG - the "diuretic hypothesis".
McMurray J
J Diabetes Complications; 2016; 30(1):3-4. PubMed ID: 26597600
[No Abstract] [Full Text] [Related]
2. The EMPA-REG study: What has it told us? A diabetologist's perspective.
DeFronzo RA
J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076
[No Abstract] [Full Text] [Related]
3. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
4. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
Jørgensen NB; Pedersen J; Vaag AA
J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
[No Abstract] [Full Text] [Related]
5. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
DeFronzo RA; Chilton R; Norton L; Clarke G; Ryder RE; Abdul-Ghani M
Diabetes Obes Metab; 2016 May; 18(5):454-62. PubMed ID: 26919068
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Rajasekeran H; Lytvyn Y; Cherney DZ
Kidney Int; 2016 Mar; 89(3):524-6. PubMed ID: 26880444
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Kosiborod M; Gause-Nilsson I; Xu J; Sonesson C; Johnsson E
J Diabetes Complications; 2017 Jul; 31(7):1215-1221. PubMed ID: 28284707
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
Peters MN; Pollock JS; Rajagopalan S
J Diabetes Complications; 2016 Mar; 30(2):189-91. PubMed ID: 26632087
[No Abstract] [Full Text] [Related]
9. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
Cherney DZ; Udell JA
Circulation; 2016 Dec; 134(24):1915-1917. PubMed ID: 27956401
[No Abstract] [Full Text] [Related]
10. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
Scheen AJ
Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
[TBL] [Abstract][Full Text] [Related]
11. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Staels B
Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
[TBL] [Abstract][Full Text] [Related]
13. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
14. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Staels B
Am J Cardiol; 2017 Jul; 120(1S):S28-S36. PubMed ID: 28606341
[TBL] [Abstract][Full Text] [Related]
16. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Laubner K; Seufert J
Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin (Jardiance) for diabetes.
Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
[No Abstract] [Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
19. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton R
Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
[TBL] [Abstract][Full Text] [Related]
20. Impact of empagliflozin in patients with diabetes and heart failure.
Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]